Developer docs
API playgroundTry for free, no card

Search company profiles

Design Therapeutics

Full company profile

uuid0000d1l

Namestring
Design Therapeutics
Legal namestring
Design Therapeutics, Inc.
Websiteurl
designtx.com
Company typeenum
Public
Founded yearint
2019
Descriptiontext

Design Therapeutics is a clinical-stage biopharmaceutical company headquartered in Carlsbad, California (NASDAQ: DSGN), founded to develop small molecule therapeutics for monogenic degenerative disorders caused by nucleotide repeat expansions. The company's core asset is its proprietary GeneTAC (Gene Targeted Chimera) platform, which engineers small molecules composed of a DNA-binding moiety linked to a ligand moiety to selectively dial gene expression up or down at disease-causing repeat sequences—without requiring gene editing or altering patient DNA. This architecture allows systemic, including CNS, distribution of a conventional small molecule while preserving wild-type gene function.

Design's pipeline targets four repeat-expansion disorders with no approved disease-modifying therapies: DT-216P2 for Friedreich ataxia (intravenous, Phase 1/2 RESTORE-FA), DT-168 for Fuchs Endothelial Corneal Dystrophy (eye drop, Phase 2 biomarker trial), DT-818 for Myotonic Dystrophy Type-1 (Phase 1 dosing initiated in Australia in H1 2026), and a preclinical Huntington's disease program targeting CAG repeats in HTT. May 2026 Phase 1/2 readout showed a 65% increase in frataxin mRNA and a 6.4-point mFARS improvement at the highest dose, with registrational path discussions planned with FDA in Q4 2026.

The business model is pre-commercial R&D with future pharmaceutical commercialization optionality; the company is currently funded by equity capital ($219.8M cash as of Q4 2025, runway into 2029) with no licensing revenue, partnerships, or commercialized products. Upon approval, distribution is expected to follow standard specialty pharmacy and hospital channels for rare disease therapeutics. The leadership team is anchored by repeat biotech operators including CEO Pratik Shah (former CEO of Auspex, acquired by Teva for $3.5B) and co-founder Aseem Ansari, the academic pioneer of synthetic transcription factors that underpin the GeneTAC platform.

Short descriptiontext

Design Therapeutics is a clinical-stage biopharmaceutical company developing proprietary GeneTAC small molecule therapeutics that selectively modulate gene expression at nucleotide repeat expansions to treat serious genetic diseases, with a clinical pipeline spanning Friedreich ataxia, Fuchs dystrophy, myotonic dystrophy, and Huntington's disease.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCarlsbad, United States
HQ citystring
Carlsbad
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
genomic medicine, small molecule therapeutics, genetic disease treatment, repeat expansion disorders, clinical-stage biotechnology
Industry3 codes
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Genomic Medicine Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Development and Commercialization
TypeOne Time License
Description

As a pre-commercial clinical-stage biotechnology company, Design Therapeutics does not currently generate revenue. The company is developing small molecule therapeutics for genetic diseases with plans to pursue regulatory approval and commercialize treatments upon successful clinical trial outcomes.

stocktitan.net
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Design Therapeutics is a clinical-stage biopharmaceutical company developing proprietary GeneTAC small molecule therapeutic candidates designed to selectively modulate gene expression at nucleotide repeat expansion mutations. Its pipeline targets serious monogenic genetic diseases with no approved disease-modifying therapies, including Friedreich ataxia (DT-216P2), Fuchs endothelial corneal dystrophy (DT-168), myotonic dystrophy type-1 (DT-818), and Huntington's disease. The GeneTAC approach uses DNA-binding and ligand moieties to dial gene expression up or down without requiring gene editing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 65% increase in frataxin mRNA levels in whole blood
+3 more records
Product overview1 text field

Design Therapeutics is a biopharmaceutical company advancing novel small molecule therapeutic candidates through its proprietary GeneTAC® (Gene Targeted Chimera) platform. The company's pipeline consists of four clinical and preclinical programs targeting nucleotide repeat expansion disorders: DT-216P2 for Friedreich Ataxia (Phase 1/2), DT-168 for Fuchs Endothelial Corneal Dystrophy (Phase 2), DT-818 for Myotonic Dystrophy Type-1 (Phase 1 planned), and a Huntington's Disease research program. The GeneTAC® platform enables selective modulation of gene expression without gene editing by using small molecules with DNA-binding and ligand moieties.

Product and service4 records
1DT-216P2
CategoryClinical-stage therapeutic candidate (small molecule)
Description

A GeneTAC small molecule therapeutic candidate for Friedreich ataxia, administered intravenously, designed to increase frataxin RNA transcription in patients with GAA repeat expansions. Currently in Phase 1/2 RESTORE-FA trial for patients with Friedreich ataxia.

2DT-168
CategoryClinical-stage therapeutic candidate (small molecule, topical)
Description

A GeneTAC small molecule designed to target CTG repeats in the TCF4 gene for Fuchs Endothelial Corneal Dystrophy, formulated as an eye drop to selectively block transcription of the expansion-containing allele. Phase 1 completed and Phase 2 biomarker trial initiated.

3DT-818
CategoryClinical-stage therapeutic candidate (small molecule)
Description

A GeneTAC small molecule designed to target CTG repeats in the DMPK gene for Myotonic Dystrophy Type-1, designed to selectively reduce transcription of the mutant expanded allele. Phase 1 MAD trial planned for H1 2026 in Australia.

4Huntington's Disease Program
CategoryPreclinical research program (small molecule)
Description

A GeneTAC small molecule program targeting CAG triplet repeats in the HTT gene for Huntington's disease, designed to selectively reduce toxic mutant HTT (mtHTT) gene product while preserving wild-type HTT (wtHTT) expression. Preclinical research program.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing stereopure oligonucleotide therapeutics for repeat expansion disorders including Huntington's disease and DM1. Most directly comparable peer as both companies target the same repeat expansion indications with novel genomic medicine approaches.

TypeDirect peer
Description

Pioneer in antisense oligonucleotide (ASO) therapeutics for genetic diseases. Develops tofersen for SOD1 ALS and has programs in Huntington's disease (tominersen collaboration with Roche), making it a directly comparable peer targeting similar repeat expansion and rare neurological disorders.

TypeEmerging player
Description

Clinical-stage gene editing company developing base editing therapies for genetic diseases including repeat expansion disorders. Competes with GeneTAC for the same Friedreich ataxia and DM1 patient populations using a different genomic medicine modality.

TypeEmerging player
Description

CRISPR-based gene editing company developing in vivo and ex vivo therapies for genetic diseases. Competes for repeat expansion disorder opportunities with a different modality approach, providing investor comparison for genomic medicine platform valuations.

TypeBroad incumbent
Description

Established RNAi therapeutics leader with multiple approved products for rare genetic diseases (Onpattro, Givlaari, Oxlumo). Comparable as a nucleic acid-based approach to genetic disease modulation, though with broader portfolio and commercial-stage operations.

TypeBroad incumbent
Description

Commercial-stage rare disease biotech with multiple approved enzyme replacement and small molecule therapies. Comparable as a strategic acquirer profile and as a benchmark for orphan disease biotech valuations reaching commercialization stage.

TypeEmerging player
Description

Clinical-stage gene therapy company developing treatments for Duchenne muscular dystrophy and other genetic diseases. Comparable as a clinical-stage genetic disease biotech with similar development timelines, capital requirements, and pipeline focus on monogenic disorders.

TypeDirect peer
Description

Biotech developing CNS-targeted small molecule therapeutics for neurological disorders including Huntington's disease. Comparable as a small molecule approach to CNS genetic/neurological diseases with similar development and clinical risk profiles.

TypeDirect peer
Description

Clinical-stage rare disease biotech developing oral small molecule therapeutics for endocrine disorders and rare diseases. Comparable as a peer-stage small molecule biotech with platform approach, multiple pipeline programs, and similar operational scale and capital structure.

TypeEmerging player
Description

Clinical-stage gene therapy company developing treatments for genetic diseases including Huntington's disease (AMT-130 in Phase 1/2). Comparable as a competing modality targeting the same Huntington's disease patient population with similar clinical timeline.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Design Therapeutics

Genomic Medicine Therapeuticsdesigntx.com

Design Therapeutics is a clinical-stage biopharmaceutical company developing proprietary GeneTAC small molecule therapeutics that selectively modulate gene expression at nucleotide repeat expansions to treat serious genetic diseases, with a clinical pipeline spanning Friedreich ataxia, Fuchs dystrophy, myotonic dystrophy, and Huntington's disease.

What Design Therapeutics does

Design Therapeutics is a clinical-stage biopharmaceutical company headquartered in Carlsbad, California (NASDAQ: DSGN), founded to develop small molecule therapeutics for monogenic degenerative disorders caused by nucleotide repeat expansions. The company's core asset is its proprietary GeneTAC (Gene Targeted Chimera) platform, which engineers small molecules composed of a DNA-binding moiety linked to a ligand moiety to selectively dial gene expression up or down at disease-causing repeat sequences—without requiring gene editing or altering patient DNA. This architecture allows systemic, including CNS, distribution of a conventional small molecule while preserving wild-type gene function.

Design's pipeline targets four repeat-expansion disorders with no approved disease-modifying therapies: DT-216P2 for Friedreich ataxia (intravenous, Phase 1/2 RESTORE-FA), DT-168 for Fuchs Endothelial Corneal Dystrophy (eye drop, Phase 2 biomarker trial), DT-818 for Myotonic Dystrophy Type-1 (Phase 1 dosing initiated in Australia in H1 2026), and a preclinical Huntington's disease program targeting CAG repeats in HTT. May 2026 Phase 1/2 readout showed a 65% increase in frataxin mRNA and a 6.4-point mFARS improvement at the highest dose, with registrational path discussions planned with FDA in Q4 2026.

The business model is pre-commercial R&D with future pharmaceutical commercialization optionality; the company is currently funded by equity capital ($219.8M cash as of Q4 2025, runway into 2029) with no licensing revenue, partnerships, or commercialized products. Upon approval, distribution is expected to follow standard specialty pharmacy and hospital channels for rare disease therapeutics. The leadership team is anchored by repeat biotech operators including CEO Pratik Shah (former CEO of Auspex, acquired by Teva for $3.5B) and co-founder Aseem Ansari, the academic pioneer of synthetic transcription factors that underpin the GeneTAC platform.

Design Therapeutics firmographics

Firmographics
Name
Design Therapeutics
Legal name
Design Therapeutics, Inc.
Website
https://designtx.com
Company type
Public
Founded year
2019
Operating status
Operating
Headcount range
51–100 employees
Short description
Design Therapeutics is a clinical-stage biopharmaceutical company developing proprietary GeneTAC small molecule therapeutics that selectively modulate gene expression at nucleotide repeat expansions to treat serious genetic diseases, with a clinical pipeline spanning Friedreich ataxia, Fuchs dystrophy, myotonic dystrophy, and Huntington's disease.
Ownership category
akta.pro rank

Design Therapeutics industry classification

Industry
Product category
Genomic Medicine Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Genomic medicine
  • Small molecule therapeutics
  • Genetic disease treatment
  • Repeat expansion disorders
  • Clinical-stage biotechnology

Where Design Therapeutics is headquartered

Location

Headquarters

HQ city
Carlsbad
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Design Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Development and Commercialization: As a pre-commercial clinical-stage biotechnology company, Design Therapeutics does not currently generate revenue. The company is developing small molecule therapeutics for genetic diseases with plans to pursue regulatory approval and commercialize treatments upon successful clinical trial outcomes.

Go-to-market motion1 record

Marketing channels3 records

Design Therapeutics product offering

Product offering

Core offering

Design Therapeutics is a clinical-stage biopharmaceutical company developing proprietary GeneTAC small molecule therapeutic candidates designed to selectively modulate gene expression at nucleotide repeat expansion mutations. Its pipeline targets serious monogenic genetic diseases with no approved disease-modifying therapies, including Friedreich ataxia (DT-216P2), Fuchs endothelial corneal dystrophy (DT-168), myotonic dystrophy type-1 (DT-818), and Huntington's disease. The GeneTAC approach uses DNA-binding and ligand moieties to dial gene expression up or down without requiring gene editing.

Product overview

Design Therapeutics is a biopharmaceutical company advancing novel small molecule therapeutic candidates through its proprietary GeneTAC® (Gene Targeted Chimera) platform. The company's pipeline consists of four clinical and preclinical programs targeting nucleotide repeat expansion disorders: DT-216P2 for Friedreich Ataxia (Phase 1/2), DT-168 for Fuchs Endothelial Corneal Dystrophy (Phase 2), DT-818 for Myotonic Dystrophy Type-1 (Phase 1 planned), and a Huntington's Disease research program. The GeneTAC® platform enables selective modulation of gene expression without gene editing by using small molecules with DNA-binding and ligand moieties.

Differentiator

Problem solved

Functional benefit

Products and services

  • DT-216P2 A GeneTAC small molecule therapeutic candidate for Friedreich ataxia, administered intravenously, designed to increase frataxin RNA transcription in patients with GAA repeat expansions. Currently in Phase 1/2 RESTORE-FA trial for patients with Friedreich ataxia.
  • DT-168 A GeneTAC small molecule designed to target CTG repeats in the TCF4 gene for Fuchs Endothelial Corneal Dystrophy, formulated as an eye drop to selectively block transcription of the expansion-containing allele. Phase 1 completed and Phase 2 biomarker trial initiated.
  • DT-818 A GeneTAC small molecule designed to target CTG repeats in the DMPK gene for Myotonic Dystrophy Type-1, designed to selectively reduce transcription of the mutant expanded allele. Phase 1 MAD trial planned for H1 2026 in Australia.
  • Huntington's Disease Program A GeneTAC small molecule program targeting CAG triplet repeats in the HTT gene for Huntington's disease, designed to selectively reduce toxic mutant HTT (mtHTT) gene product while preserving wild-type HTT (wtHTT) expression. Preclinical research program.

Quantifiable outcome

  • 65% increase in frataxin mRNA levels in whole blood
  • +3 more outcomes

Companies that use Design Therapeutics

Customer profile

Segments4 records

Ideal customer profiles2 records

Design Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Design Therapeutics partnerships and signals

Strategic signal

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Design Therapeutics competitors and assessment

Company assessment

Direct peers

  • Wave Life Sciences: Clinical-stage biotech developing stereopure oligonucleotide therapeutics for repeat expansion disorders including Huntington's disease and DM1. Most directly comparable peer as both companies target the same repeat expansion indications with novel genomic medicine approaches.
  • Ionis Pharmaceuticals: Pioneer in antisense oligonucleotide (ASO) therapeutics for genetic diseases. Develops tofersen for SOD1 ALS and has programs in Huntington's disease (tominersen collaboration with Roche), making it a directly comparable peer targeting similar repeat expansion and rare neurological disorders.
  • Sage Therapeutics: Biotech developing CNS-targeted small molecule therapeutics for neurological disorders including Huntington's disease. Comparable as a small molecule approach to CNS genetic/neurological diseases with similar development and clinical risk profiles.
  • Crinetics Pharmaceuticals: Clinical-stage rare disease biotech developing oral small molecule therapeutics for endocrine disorders and rare diseases. Comparable as a peer-stage small molecule biotech with platform approach, multiple pipeline programs, and similar operational scale and capital structure.

Emerging players

  • Beam Therapeutics: Clinical-stage gene editing company developing base editing therapies for genetic diseases including repeat expansion disorders. Competes with GeneTAC for the same Friedreich ataxia and DM1 patient populations using a different genomic medicine modality.
  • Intellia Therapeutics: CRISPR-based gene editing company developing in vivo and ex vivo therapies for genetic diseases. Competes for repeat expansion disorder opportunities with a different modality approach, providing investor comparison for genomic medicine platform valuations.
  • Solid Biosciences: Clinical-stage gene therapy company developing treatments for Duchenne muscular dystrophy and other genetic diseases. Comparable as a clinical-stage genetic disease biotech with similar development timelines, capital requirements, and pipeline focus on monogenic disorders.
  • uniQure: Clinical-stage gene therapy company developing treatments for genetic diseases including Huntington's disease (AMT-130 in Phase 1/2). Comparable as a competing modality targeting the same Huntington's disease patient population with similar clinical timeline.

Broad incumbents

  • Alnylam Pharmaceuticals: Established RNAi therapeutics leader with multiple approved products for rare genetic diseases (Onpattro, Givlaari, Oxlumo). Comparable as a nucleic acid-based approach to genetic disease modulation, though with broader portfolio and commercial-stage operations.
  • BioMarin Pharmaceutical: Commercial-stage rare disease biotech with multiple approved enzyme replacement and small molecule therapies. Comparable as a strategic acquirer profile and as a benchmark for orphan disease biotech valuations reaching commercialization stage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Design Therapeutics social profiles

Digital presence

Design Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Design Therapeutics leadership team

Management profile

Number of profiles

Profiles10 records

Design Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Design Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Design Therapeutics

What does Design Therapeutics do?

Design Therapeutics is a clinical-stage biopharmaceutical company developing proprietary GeneTAC small molecule therapeutic candidates designed to selectively modulate gene expression at nucleotide repeat expansion mutations. Its pipeline targets serious monogenic genetic diseases with no approved disease-modifying therapies, including Friedreich ataxia (DT-216P2), Fuchs endothelial corneal dystrophy (DT-168), myotonic dystrophy type-1 (DT-818), and Huntington's disease. The GeneTAC approach uses DNA-binding and ligand moieties to dial gene expression up or down without requiring gene editing.

Is Design Therapeutics a public or private company?

Design Therapeutics is a public company. It is classified as public and is currently operating.

When was Design Therapeutics founded?

Design Therapeutics was founded in 2019. It employs 51 to 100 people.

Where is Design Therapeutics based?

Design Therapeutics is headquartered in Carlsbad, United States, in the North America region.

How does Design Therapeutics make money?

One revenue line is on record: pharmaceutical Development and Commercialization.

Who are Design Therapeutics's main competitors?

Direct peers on record are Wave Life Sciences, Ionis Pharmaceuticals, Sage Therapeutics and Crinetics Pharmaceuticals. Emerging players are Beam Therapeutics, Intellia Therapeutics, Solid Biosciences and uniQure. Broad incumbents are Alnylam Pharmaceuticals and BioMarin Pharmaceutical.

Does Design Therapeutics have an API?

No public API is recorded for Design Therapeutics.

What industry is Design Therapeutics in?

Design Therapeutics's product category is Genomic Medicine Therapeutics. Its primary akta.pro industry code is HLAAACAE, Gene Therapy for Rare/Monogenic Diseases, with a secondary code of HLAAACAH, Neurology/CNS Gene Therapies. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsDesign Therapeutics (NASDAQ:DSGN) Price Target Cut to $19.00 by Analysts at Royal Bank Of CanadaRoyal Bank of Canada cut its price target on Design Therapeutics from $20 to $19, keeping an outperform rating. The stock opened at $9.67, and analysts' consensus is a Moderate Buy with a target of $18.57. The company reported a quarterly loss of $0.32 per share, beating estimates.TradingViewDesign Therapeutics, Inc. Stock 12‑Month Price Target Cut to $21.57, Implies 103% UpsideAnalysts' average price target for Design Therapeutics fell to $21.57 from $21.71, implying about 103% upside from the Nov. 4 close. The consensus remains a Buy across 8 analysts, with forecasts ranging from $19 to $26 per share.Seeking AlphaDesign Therapeutics GAAP EPS of -$0.32 beats by $0.02 (NASDAQ:DSGN)Design Therapeutics reported Q3 GAAP EPS of -$0.32, beating by $0.02. As of September 30, 2026, the company held $208.6 million in cash, cash equivalents, and investment securities.MarketBeatDesign Therapeutics (DSGN) Expected to Release Earnings on WednesdayDesign Therapeutics is expected to release Q3 2026 earnings before market open on Wednesday, November 4th, with analysts projecting a loss of $0.38 per share. The company previously beat estimates with a $0.32 loss in August, and analysts forecast a $1.41 loss for the current fiscal year. A conference call is scheduled for Thursday, November 5th.MarketBeatDesign Therapeutics, Inc. (NASDAQ:DSGN) Stock Rated "Moderate Buy" by Wall Street BrokeragesDesign Therapeutics received a consensus "Moderate Buy" rating from nine analysts, with an average 12-month price target of $17.86. The company reported a loss of $0.32 per share for the quarter, beating estimates of $0.34. Institutional investors own 56.64% of the stock.Simply Wall StCompanies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In GrowthDesign Therapeutics has a cash runway of 3.8 years with $207m in cash and $55m annual burn. Its cash burn increased 8.6% over the past year, but analysts forecast breakeven in about 4 years. The company could fund another year of growth by issuing new shares.Ticker ReportDesign Therapeutics, Inc. (NASDAQ:DSGN) Stock Has Average Target Price of $16.50 According to AnalystsDesign Therapeutics shares received an average "Moderate Buy" rating from nine analysts, with an average 1-year price target of $17.86. The company reported a quarterly loss of $0.32 per share, beating estimates of $0.34, and analysts predict a current-year loss of $1.41 per share.Seeking AlphaDesign Therapeutics: DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027Design Therapeutics is initiated with a 'Hold' rating on its GeneTAC small molecule DT-216P2 for Friedreich Ataxia. The company plans a registrational update in Q4 2026 and 12-week results in Q1 2027, with over $200M in cash supporting operations for 12+ months.American Banking and Market News43,728 Shares in Design Therapeutics, Inc. $DSGN Purchased by Bank of America Corp DEBank of America Corp DE acquired a new position in Design Therapeutics, buying 43,728 shares valued at about $633,000 in Q2. The stock opened at $12.34 with a market cap of $772.24 million, and analysts have an average "Buy" rating with a consensus price target of $17.86.Markets DailyDesign Therapeutics, Inc. (NASDAQ:DSGN) Stock Has Average Target Price of $16.50 According to BrokeragesDesign Therapeutics shares opened at $12.34, with an average broker target of $17.86 and a Moderate Buy consensus. The company reported Q2 EPS of -$0.32, beating estimates of -$0.34, and analysts expect -$1.41 EPS for the fiscal year.